• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
SUN Yushen,LI Wei,HAN Congxiao,LIU Qun,LIU Xiaoqian,LU Changfei.Analysis of 426 cases of adverse reaction reports of Latamoxef for Injection[J].Journal Of Pharmaceutical Research,2025,44(11):1,139-1,144[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2156times   Download 751次 QR Code for this article
Scan with your phone!
426例注射用拉氧头孢的不良反应报告分析
孙玉慎1,李伟1,韩丛笑2,刘群2,刘晓倩2,路长飞3
Font:Larger+|Default|Smaller-
(1.山东中医药大学,山东 济南 250355;2.山东中医药大学附属医院药学部,山东 济南 250014;3.山东省药品不良反应监测中心,山东 济南 250013)
摘要:
目的 分析注射用拉氧头孢的药品不良反应(adverse drug reaction, ADR)报告数据,为临床合理用药提供依据。方法 采用回顾性分析研究的方法,对2019年1月至2023 年12月期间,山东省药品不良反应监测中心数据库中收集到的经药品关联性评价评定为肯定、很可能以及可能的注射用拉氧头孢ADR报告,并对报告中注射用拉氧头孢所致的ADR报告中的患者年龄及性别、不良反应报告情况及ADR因果关系、原发疾病、用法用量、ADR累及器官-系统分布、ADR的发生时间、新的和严重的不良反应以及转归情况等进行统计分析。结果 共收集到426例注射用拉氧头孢所致的ADR报告,其中0~10岁分布最多,共219例次(51.41%);原患疾病以呼吸系统损害为主,共126例次(29.58%);注射用拉氧头孢的给药途径以静脉滴注给药为主,共417例次(97.89%);ADR的发生时间主要集中在用药1 h以内(67.37%);ADR累及器官-系统共涉及12项,以皮肤及附件损害最多,共456例次(71.59%);在426例ADR报告中有271例患者痊愈,154例患者好转,1例患者转归不详。结论 临床应加强对注射用拉氧头孢的用药管理,严格遵照说明书用药并加强对用药患者的监护,能够有效的减少不良反应的发生。
关键词:  注射用拉氧头孢  药品不良反应  统计分析  病例报告  合理用药  药物警戒
DOI:10.13506/j.cnki.jpr.2025.11.015
基金项目:山东中医药学会临床药学科研专项基金项目(No.SDACM202204);山东省医药卫生科技项目(No.202313010888)
Publication Date:November 25, 2025
Analysis of 426 cases of adverse reaction reports of Latamoxef for Injection
SUN Yushen1,LI Wei1,HAN Congxiao2,LIU Qun2,LIU Xiaoqian2,LU Changfei3
(1. Shandong University of Traditional Chinese Medicine, Jinan 250355, China; 2. Department of Pharmacy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250014, China; 3. Shandong Adverse Drug Reaction Monitoring Center, Jinan 250013, China)
Abstract:
Objective To analyze the adverse drug reaction( ADR )report data of latamoxef for injection, and to provide the basis for clinical rational drug use.Methods Using the method of retrospective analysis and research, the ADR reports of latamoxef for injection collected in the database of Shandong Provincial Adverse Drug Reaction Monitoring Center from January 2019 to December 2023 were evaluated as positive, probable and possible by drug relevance evaluation. The age and gender of the patients in the ADR report caused by latamoxef for injection, the report of adverse reactions and the causality of ADR, the primary disease, usage and dosage, the distribution of ADR-involved organs and systems, the occurrence time of ADR,the new and serious adverse reactions and prognosis of ADR were statistically analyzed.Results 426 cases of ADR caused by latamoxef for injection were most distributed in children aged 0-10 years old, with a total of 219( 51.41% ) cases. The primary disease was mainly respiratory infection, with a total of 126 ( 29.58% )cases. The main route of administration of latamoxef for injection was intravenous drip, with a total of 417 ( 97.89% ) cases. The occurrence time of ADR was mainly within 1 h( 67.37% ). There were 12 organs and systems involved in ADR, with the most damage to skin and accessories, a total of 456 ( 71.59% ) cases. Among the 426 ADR reports, 271 patients were cured, 154 patients were improved, and 1 patient 's outcome was unknown.Conclusion The clinical management of latamoxef for injection should be strengthened, strictly follow the instructions and strengthen the monitoring of patients, which can effectively reduce the occurrence of adverse reactions.
Key words:  Latoxefin for injection  Adverse drug reaction  Statistical analysis  Case report  Rational administration of drugs  Pharmacovigilance
Today's Visits:485    Total Visits:2383197
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.